Loading exclusive…
$ALT: EPS Beat Fails to Offset Cash Burn and Cautious MASH Outlook
Altimmune beats Q2 EPS but guidance on MASH commercialization and cash runway weighs on sentiment.
Key Points
- Q2 EPS of ($0.12) beat consensus of ($0.15) by 8%.
- Cash burn rate accelerating, raising concerns about near-term liquidity.
- Cautious guidance on MASH pipeline timeline disappoints investors.
- Stock declined ~2% post-print, signaling market focus on capital risk over earnings beat.
What To Watch
- Announcements of strategic partnerships or asset sales.
- Updates on cash runway and potential dilutive financing.
- Next quarterly cash burn rate and R&D expenditure trends.